FR940826-2-00110 FR940826-2-00056 Drug Enforcement Administration Manufacturer of Controlled Substances; Application Pursuant to ยง1301.43(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on July 15, 1994, Celgene Corporation, 7 Powder Horn Drive, Warren, New Jersey 07059, made application to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of the Schedule I controlled substance 2,5-Dimethoxyamphetamine (7396). Celgene Corporation plans to manufacture small quantities of the above controlled substance utilizing bio-catalysis to develop, manufacture and sell high value-added compounds important to pharmaceutical and agrochemical industries. Any other such applicant and any person who is presently registered with DEA to manufacture such substances may file comments or objections to the issuance of the above application and may also file a written request for a hearing thereon in accordance with 21 CFR 1301.54 and in the form prescribed by 21 CFR 1316.47. Any such comments, objections, or requests for a hearing may be addressed to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, United States Department of Justice, Washington, DC 20537, Attention: DEA Federal Register Representative (CCR), and must be filed no later than September 26, 1994. Dated: August 22, 1994. Gene R. Haislip, Deputy Assistance Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 94&hyph; 21100 Filed 8&hyph; 25&hyph;94; 8:45 am] BILLING CODE 4410&hyph; 09&hyph;M
